<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Competitive Analysis Table</title>
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <h1>Competitive Analysis</h1>
    <table id="analysisTable">
        <thead>
            <tr>
                <th>Company</th>
                <th>Company Description</th>
                <th>Product Name</th>
                <th>Product Description</th>
                <th>Primary Product Messaging and Positioning</th>
                <th>Product Value Proposition</th>
                <th>Product Features</th>
                <th>Website URL</th>
                <th>Pricing</th>
                <th>Other Assets</th>
                <th>Observations</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Roche Diagnostics</td>
                <td>Founded in 1896 in Basel, Switzerland, Roche is the one of the world’s largest biotech companies and a leader in in-vitro diagnostics, pioneering personalized healthcare.</td>
                <td>Elecsys Amyloid Plasma Panel (EAPP)</td>
                <td>The EAPP is a blood test that measures phosphorylated (pTau) 181 protein and apolipoprotein (APOE) E4 in human blood plasma. It aims to streamline the diagnostic process of Alzheimer’s disease by identifying 			    patients with a low likelihood of amyloid pathology, guiding further confirmatory testing such as amyloid positron emission tomography (PET) or cerebrospinal (CSF) testing.</td>
                <td><b>Messaging:</b><br>
•	The EAPP is positioned as an <b>innovative diagnostic tool </b> addressing the significant<b> unmet need for early and accurate diagnosis</b> of Alzheimer’s disease. <br><br>
<b>Positioning:</b><br>
•	The product is positioned as a crucial element in the diagnostic pathway for Alzheimer’s disease, potentially reducing the time to diagnosis and facilitating early intervention.
</td>
                <td>The EAPP offers a less invasive, blood-based method to identify the likelihood of amyloid pathology in patients showing symptoms of cognitive decline. The test aims to <b>streamline the diagnostic journey for patients.</b> Early diagnosis facilitated by the EAPP can enable <b>timely and accurate diagnosis</b> for patients, potentially slowing disease progression, allowing patients and families to plan their futures, and having access to future treatment options. </td>
                <td><b>Phosphorylated Tau (pTau) 181 Protein Assay:</b> Measures elevations in pTau 181, indicative of early stages of Alzheimer’s disease.<br><br>
<b>Apolipoprotein (APOE) E4 Assay:</b> Detects the most common genetic risk factor for Alzheimer’s disease
</td>
                <td><a href="https://diagnostics.roche.com/us/en/news-listing/2022/elecsys-amyloid-plasma-panel-fda-breakthrough-device-designation-alzheimers.html" target="_blank">FDA Breakthrough Device Designation News Release</a><br><br> <a href="https://diagnostics.roche.com/us/en/news-listing/2023/roche-collaboration-lilly-enhance-early-diagnosis-alzheimers-dis.html" target="_blank">Collaboration with Eli Lilly News Release</a></td>
                <td>No specific pricing information found, but it's positioned as a cost-effective alternative to a PET scan.</td>
                <td>•	<b>FDA Breakthrough Device Designation</b><br><br>
•	<b>Collaboration with Eli Lilly:</b> Enhances test credibility and collaborative strength in the Alzheimer’s diagnostic field.<br><br>
•	<b>Comprehensive Alzheimer’s Portfolio:</b> Includes digital and blood-based tests, investigational medicines, and CSF assays.<br><br>
</td>
                <td>Emphasizes collaboration with Eli Lilly on March 22, 2023</td>
            </tr>
            <tr>
                <td>C2N Diagnostics</td>
                <td>C2N Diagnostics is a pioneering molecular diagnostics company specializing in the early diagnosis and treatment of Alzheimer’s disease and related neurodegenerative disorders, based in St. Louis, MO.  Founded by researchers from Washington University School of Medicine and Lifetech Research, the company employs advanced mass spectrometry to identify crucial protein biomarkers. C₂N has developed an innovative blood-based diagnostic test for detecting brain amyloid, a key indicator of Alzheimer’s, available under CLIA in the US and CE Mark in the EU, with efforts underway for FDA approval. Their test is used in numerous collaborations globally with leading academic investigators and biopharmaceutical partners.</td>
                <td>Precivity AD®</td>
                <td>The Precivity AD test is an <b>innovative</b> test designed for patients aged 55 and older who exhibit signs of cognitive impairment or dementia. The test detects amyloid plaques in the brain, a hallmark of Alzheimer’s disease, by <b>quantifying</b> Amyloid Beta 42/40 ratio (Aϐ 42/40) and detection of Apolipoprotein E proteotype (equivalent to ApoE genotype) in blood samples using C2N’s proprietary mass spectrometry platform.</td>
                <td><b>Messaging:</b><br> 
•	The Precivity AD® test addresses the need for <b>accessible and cost-effective diagnostic testing</b> for Alzheimer’s disease. It provides healthcare providers with an innovative tool to gain <b>accurate insights</b> into Alzheimer’s pathology. <br><br>
<b>Positioning:</b><br>
•	The Precivity AD test positions itself as a <b>simple blood draw</b> that removes diagnostic testing barriers. It offers an alternative to traditional diagnostic methods like PET scans, making it easier for patients and healthcare providers to get <b>clear answers </b>and an accurate diagnosis.
</td>
                <td>The Precivity AD test delivers precise and reliable identification of amyloid plaques, enabling <b>earlier diagnosis</b> and better management of Alzheimer’s disease. It addressed a <b>critical unmet medical need</b> by providing a simple, widely accessible, and <b>minimally invasive diagnostic test for AD.</b> </td>
                <td><b>Biomarker Measurement:</b> Quantifies the Aβ42/40 ratio and detects ApoE proteotype in blood samples.<br><br>
<b>Advanced Technology:</b> Utilizes C₂N’s Stable Isotope Spike Absolute Quantitation (SISAQ™) methodology for high precision.<br><br>
<b>Algorithm-Based Score:</b> Provides an Amyloid Probability Score (APS) that indicates the likelihood of amyloid positivity on PET scans.
</td>
                <td><a href="https://precivityad.com/patients" target="_blank">Precivity AD®</a><br><br><a href="https://precivityad.com/precivityad2-patients" target="_blank">Precivity AD2</a><br><br><a href="https://precivityad.com/apoe-genetic-testing-patients" target="_blank">Precivity-ApoE - Genetic Testing</a></td>
                <td>•	Not currently covered by private insurance, Medicare or Medicaid. <br><br>
•	Patients are responsible for paying for the test out of pocket. <br><br>
•	Financial assistance program for those who qualify medically and financially.<br><br> 
o	Six-month, interest-free financing is available for patients. <br><br>
•	Working to establish reimbursement for the test
</td>
                <td>•	Currently developing additional markers of Alzheimer’s disease including p-tau217.<br><br>
o	The Precivity AD test is C2N’s initial test offering, and is expected to be a part of a future Brain Health Panel that will measure multiple pathological markers for Alzheimer’s disease and related disorders<br><br>
•	Eisai co invested $15 million in C2N Diagnostics in April 2024<br><br>
•	Tests offered through Mayo Clinic Laboratories through a non-exclusive agreement<br><br>
•	FDA Breakthrough Device Designation<br><br>
•	Offers patients ability to schedule there blood draw at a nearby location (uses map) on website: https://precivityad.com/schedule-blood-draw

</td>
                <td><a href="https://www.linkedin.com/company/c2n-diagnostics/posts/?feedView=all" target="_blank">• LinkedIn Page</a><br><br>•	High-quality content on LinkedIn, website <br><br>
•	Smaller company (~77 employees on LinkedIn)<br><br>
•	<a href="https://precivityad.com/publications-clinical-use" target="_blank">Publication library on website</a><br><br>
•	<a href="https://precivityad.com/patient-caregiver-faq " target="_blank">Patient FAQ page</a><br><br>
•	News page on website contains:<br>
o	News<br>
o	Newsletters<br>
o	Video<br>
o	Webinars<br>
o	Media Coverage</td>
            </tr>
<tr> 
<td>Quest Diagnostics </td>
<td> Quest Diagnostics (NYSE: DGX) empowers people to improve health outcomes through diagnostic insights from the world's largest clinical lab database. Serving one in three adult Americans and half the U.S. physicians and hospitals, Quest offers over 3,000 tests and is a leader in cancer diagnostics and innovative test development. With labs in major metro areas and internationally, Quest performs tests for about 550,000 patients daily through 2,250 patient service centers. The company also provides drug screening, life insurance risk assessment, and clinical trials testing for new pharmaceuticals.
</td>
<td>Quest AD-Detect®, Beta-Amyloid 42/40 Ratio, Plasma</td>
<td>The Quest AD-Detect® test is a blood-based diagnostic tool designed to assess the risk of Alzheimer's disease (AD) pathology in adults with mild cognitive impairment (MCI) or dementia. It measures the ratio of beta-amyloid 42 (Aβ42) to beta-amyloid 40 (Aβ40) in plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS).</td>
<td><b>Messaging:</b><br>
The Quest AD-Detect® offers a diagnostic option that is <b>simpler</b> than PET imaging and <b>less invasive</b> than CSF sampling.<br><br>

<b>Positioning:</b><br>
The test positions itself as a biomarker analysis for PD that is more suitable for a primary care setting.
</td>
<td>The AD-Detect® test delivers <b>precise</b> assessment of Alzheimer’s disease risk through the measurement of Aβ42/40 ratio in plasma. It addresses the need for a <b>simple</b>, widely accessible, and minimally invasive test, making <b>early detection</b> and proactive management of Alzheimer's disease more feasible.</td>
<td><b>Beta-Amyloid 42/40 ratio:</b> Quantifies the ratio of beta-amyloid 42 (Aβ42) to beta-amyloid 40 (Aβ40) in plasma<br><br>
<b>Liquid Chromatography-tandem MS (LC-MS/MS):</b> Demonstrated higher accuracy than other assays.
<td><a href="https://testdirectory.questdiagnostics.com/test/test-guides/TS_AD_Detect_BetaRatioPlasma/quest-ad-detect " target="_blank">Website</a></td>
<td>Was formerly available to purchase direct to consumer, without need to visit a doctor first<br><br>
•	Originally priced at $399</td>
<td></td>
<td>•	Public Company<br><br>
•	Conservative marketing for this product on their website<br><br>
•	Very informative – data related website page <br><br>
•	They pulled direct to consumer ordering in March 2024<br></td>

</tr>



        </tbody>
    </table>
    <script src="scripts.js"></script>
</body>
</html>
